Journal of Clinical Oncology, Vol 14, 2306-2310, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas

DV Jones Jr, R Lozano, A Hoque, A Markowitz and YZ Patt
Department of Gastrointestinal Medical Oncology and Digestive Diseases, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

PURPOSE: To evaluate the efficacy of paclitaxel administered to patients with unresectable adenocarcinomas of the gallbladder and biliary tree over 3 hours every 21 days. PATIENTS AND METHODS: Fifteen patients with unresectable and/or metastatic carcinoma of the gallbladder and bile ducts received intravenous paclitaxel over 3 hours after premedication with dexamethasone, diphenhydramine, and cimetidine. Treatment was repeated every 21 days, and one complete course of therapy was comprised of two such 21-day treatment cycles. The initial dose of paclitaxel was 170 mg/m2, and this was elevated to 200 mg/m2 due to tolerance within the initial patient cohort. RESULTS: All patients were assessable for both toxicity and response: 11 with bile duct cancer and four with gall-bladder carcinoma. Forty-three cycles of therapy were delivered during the trial (median, two), and one patient remains on treatment. No complete or partial responses were noted, although two patients achieved minor responses that lasted 2 and 2+ months, respectively. There were no deaths on this study, and all but one of the patients is still alive. The therapy was well tolerated, and hematologic and mucosal toxic effects were moderate and readily reversible, although significant neuromuscular adverse effects were noted. CONCLUSION: These findings indicate that paclitaxel, administered on this schedule, is tolerable, but is unlikely to have activity in metastatic carcinomas of the biliary tree. It is unclear whether a different regimen of paclitaxel, or another taxane, may have activity in these neoplasms.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Taieb, E. Mitry, V. Boige, P. Artru, J. Ezenfis, T. Lecomte, M. C. Clavero-Fabri, J. N. Vaillant, P. Rougier, and M. Ducreux Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma Ann. Onc., August 1, 2002; 13(8): 1192 - 1196. [Abstract] [Full Text] [PDF]

				A. Giatromanolaki, E. Sivridis, C. Simopoulos, A. Polychronidis, K. C. Gatter, A. L. Harris, and M. I. Koukourakis Thymidine Phosphorylase Expression in Gallbladder Adenocarcinomas International Journal of Surgical Pathology, July 1, 2002; 10(3): 181 - 188. [Abstract] [PDF]

				A. A. Garcia, C. G. Leichman, H. J. Lenz, J. Baranda, R. Lujan, Y. Casagrande, and L. Leichman Phase II Trial of Outpatient Schedule of Paclitaxel in Patients with Previously Untreated Metastatic, Measurable Adenocarcinoma of the Stomach Jpn. J. Clin. Oncol., June 1, 2001; 31(6): 275 - 278. [Abstract] [Full Text] [PDF]

				N.-O. Ku, X. Zhou, D. M. Toivola, and M. B. Omary The cytoskeleton of digestive epithelia in health and disease Am J Physiol Gastrointest Liver Physiol, December 1, 1999; 277(6): G1108 - G1137. [Abstract] [Full Text] [PDF]